The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites

Structure

Volumn 8, Issue 4, 2000, Pages 397-405

  Fa, Ming ^a   Bergström, Fredrik ^a   Hägglöf, Peter ^a   Wilczynska, Malgorzata ^a   Johansson, Lennart B Å ^a   Ny, Tor ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cross linking; Donor donor energy migration; Fluorescence; Intramolecular distance; PAI 1; Serpin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UROKINASE;

ANISOTROPY; ARTICLE; COMPLEX FORMATION; CROSS LINKING; ENERGY; ENZYME INHIBITOR COMPLEX; FLUORESCENCE; MOLECULAR INTERACTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

EID: 0034656014     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00121-0     Document Type: Article

References (36)

1. Huber R., Carrell R.W. Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry. 28:1989;8951-8966.
2. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269:1994;15957-15960.
3. Gils A., Declerck P.J. Structure-function relationships in serpins: current concepts and controversies. Thromb. Haemost. 80:1998;531-541.
4. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204:1992;433-451.
5. Carrell R.W., Evans D.L.I. Serpins: mobile conformations in a family of proteinase inhibitors. Curr. Opin. Struct. Biol. 2:1992;438-446.
6. Elliott P.R., Abrahams J.P., Lomas D.A. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275:1998;419-425.
7. Mottonen J., Goldsmith E.J.et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 355:1992;270-273.
8. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177:1984;531-557.
9. Whisstock J., Lesk A.M., Carrell R. Modeling of serpin-protease complexes: antithrombin-thrombin, α1-antitrypsin (358Met→Arg)-thrombin, α1-antitrypsin (358Met→Arg)-trypsin, and antitrypsin-elastase. Proteins. 26:1996;288-303.
10. Aertgeerts K., De Ranter C.J., Booth N.A., Declerck P.J. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases. J. Struct. Biol. 118:1997;236-242.
11. Wilczynska M., Fa M., Karolin J., Ohlsson P.I., Johansson L.B-Å., Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat. Struct. Biol. 4:1997;354-357.
12. Wright H.T., Scarsdale J.N. Structural basis for serpin inhibitor activity. Proteins. 22:1995;210-225.
13. Stratikos E., Gettins P.G.W. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive centre loop into β-sheet A. Proc. Natl Acad. Sci. USA. 96:1999;4808-4813.
14. Nilsson T., Wiman B. On the structure of the stable complex between plasmin and α-2-antiplasmin. FEBS Lett. 142:1982;111-114.
15. Lawrence D.A., Shore J.D.et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol. Chem. 270:1995;25309-25312.
16. Wilczynska M., Fa M., Ohlsson P.I., Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive centre loop is cleaved in the native protease-inhibitor complex. J. Biol. Chem. 270:1995;29652-29655.
17. Egelund R., Rodenburg K.W., Andreasen P.A., Rasmussen M.S., Guldberg R.E., Petersen T.E. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry. 37:1998;6375-6379.
18. Plotnick M.I., Mayne L., Schechter N.M., Rubin H. Distortion of the active site of chymotrypsin complexed with a serpin. Biochemistry. 35:1996;7586-7590.
19. Stavridi E.S., Cooperman B.S.et al. Structural change in α-chymotrypsin induced by complexation with α1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry. 35:1996;10608-10615.
20. Kaslik G., Graf L.et al. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry. 36:1997;5455-5464.
21. Lawrence D.A., Strandberg L., Ericson J., Ny T. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J. Biol. Chem. 265:1990;20293-20301.
22. Schulze A.J., Frohnert P.W., Engh R.A., Huber R. Evidence for the extent of insertion of the active site loop of intact α1 proteinase inhibitor in β-sheet A. Biochemistry. 31:1992;7560-7565.
23. Bjork I., Nordling K., Olson S.T. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A β-sheet of the inhibitor during trapping of target proteinases. Biochemistry. 32:1993;6501-6505.
24. Shore J.D., Ginsburg D.et al. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive centre loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270:1995;5395-5398.
25. Fa M., Karolin J., Aleshkov S., Strandberg L., Johansson L.B-Å., Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive centre upon interactions with target proteases, vitronectin and heparin. Biochemistry. 34:1995;13833-13840.
26. Stratikos E., Gettins P.G. Major proteinase movement upon stable serpin-proteinase complex formation. Proc. Natl Acad. Sci. USA. 94:1997;453-458.
27. Stratikos E., Gettins P.G.W. Mapping the serpin-proteinase complex using single cysteine variants of α1-proteinase inhibitor Pittsburgh. J. Biol. Chem. 273:1998;15582-15589.
28. Karolin J., Fa M., Wilczynska M., Ny T., Johansson L.B-Å. Donor-donor energy migration for determining intramolecular distances in proteins: I. Application of a model to the latent plasminogen activator inhibitor-1 (PAI-1). Biophys. J. 74:1998;11-21.
29. Bergström F., Hägglöf P., Karolin J., Ny T., Johansson L.B-Å. The use of site directed fluorophore labeling and donor-donor energy migration to investigate solution structure and dynamics in proteins. Proc. Natl Acad. Sci. USA. 92:1999;12477-12481.
30. van der Meer B.W., Coker G.I., Chen S-Y.S. Resonance Energy Transfer Theory and Data. 1994;VCH Publisher Inc, New York.
31. Lawrence D., Strandberg L., Grundstrom T., Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur. J. Biochem. 186:1989;523-533.
32. Strandberg L., Karolin J., Johansson L.B-Å., Fa M., Aleshkov S., Ny T. Fluorescence studies on plasminogen activator inhibitor 1: reactive centre cysteine mutants remain active after fluorophore attachment. Thromb. Res. 76:1994;253-267.
33. Kvassman J-O., Shore J.D. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography. Fibrinolysis. 9:1999;215-221.
34. Johansson L.B-Å., Edman P., Westlund P-O. Energy migration and rotational motion within bichromophoric molecules. II. A derivation of the fluoresence anisotropy. J. Chem. Phys. 105:1996;10896-10904.
35. Aertgeerts K., DeBondt H.L., De Ranter C.J., Declerck P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 2:1995;891-987.
36. Aertgeerts K., DeBondt H.L., De Ranter C.J., Declerck P.J. A model of reactive form of plasminogen activator inhibitor-1. J. Struct. Biol. 113:1994;239-245.